Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Acute Myeloid Leukemia

Acute Myeloid Leukemia

235

Pipeline Programs↗

408

Active Trials↗

151

Companies Involved↗

Acute Myeloid Leukemia is a highly competitive landscape with 235 programs across 151 companies. The most active players are Lomond Therapeutics Holdings, Inc., Institut de Recherches Internationales Servier, Actinium Pharmaceuticals. 39 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

91/100

Pipeline Velocity

90/100

Mech. Concentration

10/100

Completion Rate

65/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Lomond Therapeutics Holdings, Inc.

4 programs

Institut de Recherches Internationales Servier

2 programs

Actinium Pharmaceuticals

1 program

Ascentage Pharma Group Inc.

1 program

Aptose Biosciences Inc.

1 program

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

1 program

Pipeline

Programs by Phase

Preclinical41

EP0042

Ellipses Pharma

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Antibiotic

Pfizer

Patients With Antifungal Prophylaxis

University Hospital, Brest

Atra+venetoclax+azacitidine

The First Affiliated Hospital of Soochow University

Phase 182

Cobimetinib

Roche

Etoposide Phosphate

German Society for Pediatric Oncology and Hematology GPOH gGmbH

CLL-1.CAR T Cells

Baylor College of Medicine

BXCL701

Georgetown University

Zoledronate

Mario Negri Institute for Pharmacological Research

Phase 273

Carboplatin

Avyxa

Metformin

EMD Serono

Topotecan Hydrochloride

Meitheal

Cladribine

EMD Serono

ASTX727

Taiho Oncology, Inc.

Phase 339

Pevonedistat

Takeda

Melphalan

Apotex Inc.

Tacrolimus

Veloxis Pharmaceuticals

G-CSF

Arog Pharmaceuticals, Inc.

Granulocyte Colony-Stimulating Factor

Sanofi

Approved

No programs

Analysis

Modality Breakdown

75%

Small molecule

159 of 212 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 212 classified programs, each share of the total. Modality classified for 95% of 235 pipeline programs.

Analysis

Trial Status

1,174

clinical trials

Completed431 · 37%

Recruiting231 · 20%

Terminated173 · 15%

Active, not recruiting103 · 9%

Unknown status98 · 8%

Not yet recruiting69 · 6%

Other69 · 6%

Clinical Trials

Trial Activity

1174 trials

The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized Trial

Recruiting·GGruppo Italiano Malattie EMatologiche dell'Adulto·Preclinical·NCT07912684·75 enrolled

Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)

Recruiting·KKeystone Nano, Inc·Phase 1·NCT04716452·15 enrolled

A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06484062·54 enrolled

A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Recruiting·UUniversity of Ulm·Phase 3·NCT04628026·650 enrolled

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05564390·2,000 enrolled

Phase 1 First-in-Human Multi-Region Clinical Trial of ORM-1153 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Other Hematological Malignancies With CD123 Expression

Recruiting·OOrum Therapeutics USA, Inc.·Phase 1·NCT07809906·42 enrolled

A Randomized Phase III, Global, Multicentre, Open Label Clinical Trial Comparing Venetoclax Azacytidine and Quizartinib Versus Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia Patients Unelegible for Standard Induction Chemotherapy

Recruiting·PPETHEMA Foundation·Phase 3·NCT07478991·376 enrolled

A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH SubStudy

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05554406·335 enrolled

A Randomized Phase II Trial of ASTX727 With Standard Duration Versus Shorter Duration of Venetoclax in Genomically Heterogenous AML Among Adults Aged 60 or Older and Less Fit for Intensive Therapy: A MyeloMATCH Substudy

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT07437950·126 enrolled

Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT

Recruiting·PPriothera SAS·Phase 3·NCT05429632·366 enrolled

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Recipients With Hematologic Malignancies (HM)

Recruiting·UUniversity of Florida·Preclinical·NCT05322850·40 enrolled

Phase II Study of Cytarabine + Daunorubicin (7 + 3) + Gemtuzumab Ozogamicin vs. Cytarabine + Daunorubicin (7 + 3) + Venetoclax for the Treatment of Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia (CBF-AML) in Younger Adults: A MyeloMATCH Substudy

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06917911·162 enrolled

A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1/2 Study and Treated With ARD103 CAR-T Cell Therapies

Recruiting·AARCE Therapeutics, Inc.·N/A·NCT06906380·49 enrolled

CAREFit-BMT Program to Improve Cardiac Reserve in High-Risk Acute Myeloid Leukemia Patients Preparing to Undergo Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting·UUniversity of Washington·Preclinical·NCT07616921·30 enrolled

Phase I Study of Autologous CD4+ and CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Treatment of MRD-Positive AML

Recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT07645469·9 enrolled

Page 1 of 79

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)